Skip to content

Inhibitor Therapeutics, Inc.

INTI

CIK 0001042418

← back to feed
Revenue (TTM)
$0
Q1 May 2026
Net Income (TTM)
−$2.69M
+1.2% YoY Q1 May 2026
EPS Diluted (TTM)
$0.00
0.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$1.29M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
172.57M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings